Northland Biotech Overview
- Year Founded
-
2004
- Status
-
Private
- Employees
-
193
- Latest Deal Type
-
IPO
Northland Biotech General Information
Description
Beijing Northland Biotech Co Ltd is engaged in technology transfer, technical services, production and sales of ophthalmic drugs, contract manufacturing, and contract research and development. The company's independently developed biopharmaceutical, NL003, has completed Phase III clinical trials this year.
Contact Information
Website
www.northland-bio.comCorporate Office
- A406, Zhongguancun Biomedical Park
- No. 5 Shangdi Kaixing Road, Haidian District
- Beijing
- China
Corporate Office
- A406, Zhongguancun Biomedical Park
- No. 5 Shangdi Kaixing Road, Haidian District
- Beijing
- China
Northland Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. IPO | 15-Nov-2021 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 09-Jan-2019 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 24-Mar-2016 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 02-Jul-2014 | $11.6M | $11.6M | Completed | Generating Revenue | |
| 1. IPO | 18-Feb-2009 | Completed | Profitable |
Northland Biotech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 7,230,000 | $1.45 | $1.45 | 1x | $1.45 | 6.45% |
Northland Biotech Patents
Northland Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3909974-A1 | Human hepatocyte growth factor mutant and uses thereof | Pending | 07-Jan-2019 | ||
| EP-3909974-A4 | Human hepatocyte growth factor mutant and uses thereof | Pending | 07-Jan-2019 | ||
| US-12264186-B2 | Human hepatocyte growth factor mutant and uses thereof | Active | 07-Jan-2019 | ||
| US-20220064242-A1 | Human hepatocyte growth factor mutant and uses thereof | Active | 07-Jan-2019 | ||
| WO-2020143515-A1 | Human hepatocyte growth factor mutant and uses thereof | Inactive | 07-Jan-2019 | C07K14/4753 |
Northland Biotech Signals
Northland Biotech Investments (2)
Northland Biotech’s most recent deal was a Joint Venture with Joint Venture (Epi Biotech / Northland Biotech). The deal was made on 14-Apr-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Joint Venture (Epi Biotech / Northland Biotech) | 14-Apr-2025 | Joint Venture | Clinics/Outpatient Services | ||
| Huonland | 03-Aug-2012 | Joint Venture | Pharmaceuticals |
Northland Biotech ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Northland Biotech FAQs
-
When was Northland Biotech founded?
Northland Biotech was founded in 2004.
-
Where is Northland Biotech headquartered?
Northland Biotech is headquartered in Beijing, China.
-
What is the size of Northland Biotech?
Northland Biotech has 193 total employees.
-
What industry is Northland Biotech in?
Northland Biotech’s primary industry is Drug Discovery.
-
Is Northland Biotech a private or public company?
Northland Biotech is a Private company.
-
What is Northland Biotech’s current revenue?
The current revenue for Northland Biotech is .
-
How much funding has Northland Biotech raised over time?
Northland Biotech has raised $26.3M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process